Deadly ‘Superbug’ Is Spreading Across US As Drug Resistance Grows, Researchers Warn
Scientists are warning that a dangerous, drug-resistant fungus already entrenched in U.S. hospitals is becoming more formidable across the globe, even as new research points to possible breakthroughs in treatment.
Candida auris, commonly referred to as C. auris, has expanded rapidly worldwide and is increasingly able to evade both antifungal drugs and the human immune system, according to a comprehensive scientific review released in early December by researchers at the Hackensack Meridian Center for Discovery and Innovation.
The review echoes earlier alerts from the Centers for Disease Control and Prevention, which has classified C. auris as an “urgent antimicrobial threat.” It is the first fungal pathogen to receive that designation, a reflection of the sharp rise in U.S. cases, particularly within hospitals and long-term care facilities.
CDC data indicate that roughly 7,000 cases were detected across dozens of states in 2025, and the pathogen has now been identified in at least 60 countries worldwide.
The analysis, published in the journal Microbiology and Molecular Biology Reviews, outlines why the fungus has proven so difficult to control, citing outdated diagnostic tools and a limited arsenal of effective treatments. The review was authored by Dr. Neeraj Chauhan of Hackensack Meridian CDI in New Jersey, Dr. Anuradha Chowdhary of the University of Delhi’s Medical Mycology Unit, and Dr. Michail Lionakis, head of the clinical mycology program at the National Institutes of Health.
The researchers emphasized the urgency of expanding therapeutic options and improving detection.
Their work highlights the need to create “novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests, and to develop immune- and vaccine-based adjunct modalities for the treatment of high-risk patients,” they said in a statement.
“In addition, future efforts should focus on raising awareness about fungal disease through developing better surveillance mechanisms, especially in resource-poor countries,” they added. “All these developments should help improve the outcomes and prognosis of patients afflicted by opportunistic fungal infections.”
First discovered in 2009 after being isolated from an ear sample in Japan, C. auris has since spread to numerous regions, including the United States. In some cases, outbreaks have been severe enough to force the closure of hospital intensive care units, the researchers noted.
The fungus is particularly dangerous for patients who are already critically ill, including those on ventilators or with compromised immune systems. Some estimates suggest that about half of infected patients may die.
Unlike many fungal organisms, C. auris can persist on human skin and survive for long periods on hospital surfaces and medical equipment, making it especially difficult to eliminate in healthcare environments.
“It is resistant to multiple antifungal drugs, and it tends to spread in hospital settings, including on equipment being used on immunocompromised and semi-immunocompromised patients, such as ventilators and catheters,” Dr. Marc Siegel, Fox News senior medical analyst and a clinical professor of medicine at NYU Langone, previously told Fox News Digital.
Misidentification is another major challenge, as C. auris is often confused with other infections, slowing treatment and containment efforts.
“Unfortunately, symptoms such as fever, chills and aches may be ubiquitous, and it can be mistaken for other infections,” Siegel said.
In September, Siegel noted that intensive research efforts were underway to find new ways to combat the fungus.
Currently, only four main classes of antifungal medications exist, and C. auris has already demonstrated resistance to many of them. Although three new antifungal drugs have either been approved or are nearing approval, experts caution that drug development has not kept pace with the pathogen’s rapid evolution.
Despite the grim outlook, recent findings suggest a potential path forward.
In a separate study published in December, researchers at the University of Exeter in England identified what may be a critical vulnerability in C. auris while studying the organism in a living-host model.
The scientists found that during infection, the fungus switches on specific genes that allow it to scavenge iron, a nutrient essential for its survival. Their findings were published in the Nature portfolio journal Communications Biology.
Because iron is vital to the pathogen, researchers believe that targeting this process could halt infections or allow existing antifungal drugs to be repurposed.
“We think our research may have revealed an Achilles’ heel in this lethal pathogen during active infection,” said Dr. Hugh Gifford, a clinical lecturer at the University of Exeter and a co-author of the study.
As scientists continue working to better understand and counter the fungus, public health officials stress that strict infection-control practices, rapid diagnosis, and sustained investment in new therapies remain essential.
Experts also emphasize that Candida auris does not pose a danger to healthy individuals.
{Matzav.com}
